LIXT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LIXT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Lixte Biotechnology Holdings's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $-0.24.
The industry rank for Lixte Biotechnology Holdings's Net-Net Working Capital or its related term are showing as below:
The historical data trend for Lixte Biotechnology Holdings's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lixte Biotechnology Holdings Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net-Net Working Capital | Get a 7-Day Free Trial | -1.02 | 1.09 | 0.74 | 0.88 | 0.17 |
Lixte Biotechnology Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net-Net Working Capital | Get a 7-Day Free Trial | 0.20 | -0.59 | 0.58 | 0.17 | -0.24 |
For the Biotechnology subindustry, Lixte Biotechnology Holdings's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Lixte Biotechnology Holdings's Price-to-Net-Net-Working-Capital falls into.
Lixte Biotechnology Holdings's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as
Net-Net Working Capital | (A: Dec. 2023 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (4.203 | + | 0.75 * 0 | + | 0.5 * 0 | - | 0.314 |
- | 3.5 | - | 0) | / | 2.24929 | ||
= | 0.17 |
Lixte Biotechnology Holdings's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as
Net-Net Working Capital | (Q: Mar. 2024 ) | ||||||
= | (Cash, Cash Equivalents, Marketable Securities | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (3.414 | + | 0.75 * 0 | + | 0.5 * 0 | - | 0.463 |
- | 3.5 | - | 0) | / | 2.24929 | ||
= | -0.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
Lixte Biotechnology Holdings (NAS:LIXT) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.
Rene Bernards | director | KONINGSVAREN 37, ABCOUDE P7 1391AD |
Van Der Baan Bastiaan Jeroen | director | HOGEWEG 4-H, AMSTERDAM P7 1098CB |
Eric Forman | 10 percent owner | 117 E. 29TH ST., APT. 5A, NEW YORK NY 10016 |
Regina Brown | director | 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733 |
Glenn Krinsky | 10 percent owner | C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067 |
Yun Yen | director | 1301 OAKLAWN ROAD, ARCADIA CA 91006 |
Robert Greenberg | 10 percent owner | SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266 |
Gil Schwartzberg | 10 percent owner | 269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212 |
Philip F Palmedo | director | 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067 |
John S Kovach | director, 10 percent owner, officer: Pres., CFO & Secty | 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067 |
Stephen J. Forman | director | 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733 |
Hung Tak Ho | 10 percent owner | MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000 |
Robert N Weingarten | officer: Vice President and CFO | 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367 |
James Miser | officer: Chief Medical Officer | 680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101 |
Jane Merrill Riggs | 10 percent owner | 4852 SAINT ANDRES AVENUE, LA VERNE CA 91750 |
From GuruFocus
By Marketwired • 06-23-2023
By PRNewswire PRNewswire • 04-14-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Marketwired • 10-09-2023
By GuruFocusNews GuruFocusNews • 06-15-2022
By sperokesalga sperokesalga • 02-14-2023
By Marketwired • 07-17-2023
By sperokesalga sperokesalga • 06-02-2023
By PRNewswire PRNewswire • 04-13-2022
By Stock market mentor Stock market mentor • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.